Literature DB >> 31497854

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.

Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen, Heikki V Huikuri, Isabelle Johansson, Peter Jüni, Maddalena Lettino, Nikolaus Marx, Linda G Mellbin, Carl J Östgren, Bianca Rocca, Marco Roffi, Naveed Sattar, Petar M Seferović, Miguel Sousa-Uva, Paul Valensi, David C Wheeler.   

Abstract

Entities:  

Keywords:  Guidelines; cardiovascular diseases; cardiovascular risk assessment; diabetes mellitus; epidemiology; impaired glucose tolerance; patient management; patient-centred care; pharmacological treatment; prevention; revascularization; risk factors

Mesh：

Year:  2020        PMID： 31497854     DOI： 10.1093/eurheartj/ehz486

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  697 in total

1.  Beneficial Agents for Patients With Type 2 Diabetes and Cardiovascular Disease or Obesity: Utilization in an Era of Accumulating Evidence.

Authors:  Kelsey Buckley; Kathleen A Fairman
Journal:  Clin Diabetes       Date:  2020-04

Review 2.  Quality of Diabetes Care in the USA.

Authors:  Ben Alencherry; Dennis Bruemmer
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

3.  Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews.

Authors:  Emanuel Raschi; Matteo Bianchin; Milo Gatti; Alessandro Squizzato; Fabrizio De Ponti
Journal:  Drug Saf       Date:  2019-12       Impact factor: 5.606

Review 4.  From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.

Authors:  Ofri Mosenzon; Stefano Del Prato; Meir Schechter; Lawrence A Leiter; Antonio Ceriello; Ralph A DeFronzo; Itamar Raz
Journal:  Cardiovasc Diabetol       Date:  2021-04-28       Impact factor: 9.951

Review 5.  Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes.

Authors:  Yasaman Ghorbani; Katherine J P Schwenger; Johane P Allard
Journal:  Eur J Nutr       Date:  2021-03-02       Impact factor: 5.614

6.  Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.

Authors:  Brahim Redouane; Stephen J Greene; Marat Fudim; Muthiah Vaduganathan; Andrew P Ambrosy; Jie-Lena Sun; Adam D DeVore; Steven E McNulty; Robert J Mentz; Adrian F Hernandez; G Michael Felker; Lauren B Cooper; Barry A Borlaug; Eric J Velazquez; Kenneth B Margulies; Abhinav Sharma
Journal:  Circ Heart Fail       Date:  2020-05-04       Impact factor: 8.790

Review 7.  Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis.

Authors:  Anne Grete Semb; Eirik Ikdahl; Grunde Wibetoe; Cynthia Crowson; Silvia Rollefstad
Journal:  Nat Rev Rheumatol       Date:  2020-06-03       Impact factor: 20.543

8.  Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes.

Authors:  Nick S R Lan; Bu B Yeap; P Gerry Fegan; Gillian Green; James M Rankin; Girish Dwivedi
Journal:  Int J Cardiovasc Imaging       Date:  2020-09-21       Impact factor: 2.357

Review 9.  Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes: a Review of the Evidence.

Authors:  Mohammed E Al-Sofiani; Robert Derenbecker; Michael Quartuccio; Rita R Kalyani
Journal:  Curr Diab Rep       Date:  2019-09-23       Impact factor: 4.810

Review 10.  Quality of smoking cessation advice in guidelines of tobacco-related diseases: An updated systematic review.

Authors:  Winifred Ekezie; Rachael L Murray; Sanjay Agrawal; Ilze Bogdanovica; John Britton; Jo Leonardi-Bee
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.